Prostate cancer (PCa) is by far the most commonly diagnosed cancer in men worldwide.
Despite sensitivity to androgen deprivation, patients with advanced disease eventually …

Prostate cancer (PCa) represents the most frequently diagnosed cancer in men. Cisplatin,
also known as cis-diamminedichloroplatinum (DDP), is a standard chemotherapeutic agent …

A stress adaptation pathway termed the integrated stress response has been suggested to
be active in many cancers including prostate cancer (PCa). Here, we demonstrate that the …

Abstract The PI3K–AKT pathway has pleiotropic effects and its inhibition has long been of
interest in the management of prostate cancer, where a compensatory increase in PI3K …

Prostate cancer progression is significantly affected by its tumor microenvironment, in which
mesenchymal cells play a crucial role. Stromal cells are modified by cancer mutations …

Purpose Resistance to androgen-deprivation therapies and progression to so-called
castrate-resistant prostate cancer (CRPC) remain challenges in prostate cancer (PCa) …

Metastatic and castration-resistant disease is a fatal manifestation of prostate cancer (PCa).
The mechanism through which resistance to androgen deprivation in PCa is developed …

The circadian system is an innate clock mechanism that governs biological processes on a
near 24-hour cycle. Circadian rhythm disruption (ie, misalignment of circadian rhythms) …

Cancer and cancer therapies can have a negative impact on bone health. Because cancer
is a common diagnosis, survivorship concerns for osteoporosis and fragility fractures are an …

Aldo-Keto Reductase Family 1 Member C3 (AKR1C3), also known as type 5 17β-
hydroxysteroid dehydrogenase (17β-HSD5) or prostaglandin F (PGF) synthase, functions as …